Evidence map›Paper›PMID 21472711›Full record

ArticleCancer2011

Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.

N Jewel Samadder, Bhramar Mukherjee, Shu-Chen Huang, Jaeil Ahn, Hedy S Rennert, Joel K Greenson, Gad Rennert, Stephen B Gruber

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Diacerein treatment prevents colitis-associated cancer in mice.World journal of clinical oncology · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

N Jewel SamadderDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48105, USA. sgruber@med.umich.edu
Bhramar Mukherjee
Shu-Chen Huang
Jaeil Ahn
Hedy S Rennert
Joel K Greenson
Gad Rennert
Stephen B Gruber
University of Michigan–Ann Arbor · USClalit Health Services · ILTechnion – Israel Institute of Technology · IL

Funding

MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
Synergism of Gene and Environment in Cancer Studies: A New Bayesian ApproachR03CA130045 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MUKHERJEE, BHRAMAR · 2007 to 2008
$144k
NCI NIH HHS R01 CA081488NCI NIH HHS R03 CA130045
6 · The paper itself

Abstract

backgroundStatins and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with reduced risk of colorectal cancer (CRC) in some studies. The objective of this study was to quantify the relative risk of inflammatory bowel disease (IBD) as a risk factor for CRC and to estimate whether this risk may be modified by long-term use of NSAIDs or statins.

methodsThe Molecular Epidemiology of Colorectal Cancer study is a population-based, case-control study of incident colorectal cancer in northern Israel and controls matched by age, sex, clinic, and ethnicity. Personal histories of IBD and medication use were measured by structured, in-person interview. The relative risk of IBD and effect modification by statins and NSAIDs were quantified by conditional and unconditional logistic regression.

resultsAmong 1921 matched pairs of CRC cases and controls, a self-reported history of IBD was associated with a 1.9-fold increased risk of CRC (95% confidence interval [CI], 1.12-3.26). Long-term statin use was associated with a reduced risk of both IBD-associated CRC (odds ratio [OR] = 0.07; 95% CI, 0.01-0.78) and non-IBD CRC (OR = 0.49; 95% CI, 0.39-0.62). Stratified analysis suggested that statins may be more protective among those with IBD (ratio of OR = 0.14; 95% CI, 0.01-1.31; P = .51), although not statistically significant. NSAID use in patients with a history of IBD was suggestive of reduced risk of CRC but did not reach statistical significance (OR = 0.47; 95% CI, 0.12-1.86).

conclusionsThe risk of CRC was elevated 1.9-fold in patients with IBD. Long-term statin use was associated with reduced risk of CRC in patients with IBD.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalColorectal NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammatory Bowel DiseasesMaleMiddle AgedRiskSelf ReportAnti-Inflammatory Agents, Non-SteroidalHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID21472711
PMCPMC3117060
OpenAlexW2093720801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.